We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
ANGLE
FDA approval awaited, LDT data expected H122Allergy Therapeutics
Commercialising and developing a differentiated portfolioNexstim
Admirable execution on 2021 strategic goalsAvacta
AffiDX LFT sales paused to improve Omicron detectionAvacta
Consumer testing CE mark received for AffiDX LFTFutura Medical
Management update details degree of 2021 progressAvacta
AVA6000 set to start US Phase I studies in early-2022MaxCyte
Nkarta signs SPL to accelerate its NK cell therapiesAllergy Therapeutics
Positive top line G309 results for Grass MATA MPLRedx Pharma
R&D update: RXC004 and RXC007 in the spotlight